Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-21015
Evers, S; Afra, J; Frese, A; Goadsby, P J; Linde, M; May, A; Sándor, P S (2009). EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. European Journal of Neurology, 16(9):968-981.
|PDF - Registered users only|
BACKGROUND: Migraine is one of the most frequent disabling neurological conditions with a major impact on the patients' quality of life. OBJECTIVES: To give evidence-based or expert recommendations for the different drug treatment procedures in the particular migraine syndromes based on a literature search and the consensus of an expert panel. METHODS: All available medical reference systems were screened for the range of clinical studies on migraine with and without aura and on migraine-like syndromes. The findings in these studies were evaluated according to the recommendations of the European Federation of Neurological Societies (EFNS) resulting in level A, B, or C recommendations and good practice points. RECOMMENDATIONS: For the acute treatment of migraine attacks, oral non-steroidal antiinflammatory drug (NSAID) and triptans are recommended. The administration should follow the concept of stratified treatment. Before intake of NSAID and triptans, oral metoclopramide or domperidone is recommended. In very severe attacks, intravenous acetylsalicylic acid or subcutaneous sumatriptan are drugs of first choice. Status migrainosus can be treated by cortoicosteroids, although this is not universally held to be helpful, or dihydroergotamine. For the prophylaxis of migraine, betablockers (propranolol and metoprolol) flunarizine, valproic acid, and topiramate are drugs of first choice. Drugs of second choice for migraine prophylaxis include amitriptyline, naproxen, petasites, and bisoprolol.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology|
|DDC:||610 Medicine & health|
|Deposited On:||30 Sep 2009 10:39|
|Last Modified:||27 Nov 2013 18:25|
|Additional Information:||The definitive version is available at www.blackwell-synergy.com|
|Citations:||Web of Science®. Times Cited: 126|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page